Drug intelligence / Profile preview

APB-101

Development stage: Preclinical
Lead developer: Apic Bio
Modality: Gene Therapies

Overview

APB-101 is a gene therapy developed by Apic Bio, a company spun out of the University of Massachusetts Medical School (UMMS). It is being advanced for the treatment of Alpha-1 Antitrypsin Deficiency. The development of APB-101 is supported by Series A financing, which also funds other gene therapy programs by Apic Bio.

Targets

SERPINA1 Z (Alpha-1-antitrypsin Z variant protein)

Beyond the preview

Go deeper on APB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APB-101.

Explore the full profile